Mabwell (Shanghai) Bioscience Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05773937
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing University Cancer Hospital, Beijing, Beijing, China
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- TumorPulmonary Fibrosis
- Interventions
- Drug: 9MW3811 injectionDrug: Placebo
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05740475
- Locations
- 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
6MW3511 in Patients With Advanced Solid Tumor
Phase 1
Not yet recruiting
- Conditions
- Solid Tumors
- Interventions
- Drug: Intravenous Infusion
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT05524194
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Phase 1
Recruiting
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Drug: 6MW3211 injection with Intravenous Infusion
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05448599
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05446688
A Clinical Study of 6MW3211 in Patients With Renal Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05440045
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05431569
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 216
- Registration Number
- NCT05416749
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medicial college, Bengbu, Anhui, China
🇨🇳Hunan cancer hospital, Changsha, Hunan, China
🇨🇳Jian Zhang, Shanghai, Shanghai, China
A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections
Phase 2
- Conditions
- Skin Infection
- Interventions
- Combination Product: 9MW1411 injection 2 combined with LinezolidCombination Product: 9MW1411 injection placebo combined with LinezolidCombination Product: 9MW1411 injection 1 combined with Linezolid
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05339802
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 346
- Registration Number
- NCT05324774
- Locations
- 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China